IMOVAX® Rabies
Indication
IMOVAX Rabies vaccine is indicated for active, pre- and post-exposure immunization against rabies.
Safety Information
The most common local and systemic adverse reactions to IMOVAX Rabies vaccine may include injection site pain, erythema, and swelling; headache, nausea, and muscle aches. Other adverse reactions may occur. Once initiated for post-exposure treatment rabies vaccination should not be interrupted or discontinued because of mild local or systemic adverse reactions. Usually such reactions can be successfully managed with anti-inflammatory and antipyretic agents. Vaccination with IMOVAX Rabies vaccine may not protect all individuals.
Before administering IMOVAX Rabies vaccine, please see accompanying full Prescribing Information.
IMOGAM® Rabies–HT
Indication
IMOGAM Rabies-HT immune globulin is given for passive immunization of individuals suspected of exposure to rabies.
Safety Information
Side effects to the IMOGAM Rabies-HT immune globulin include injection site tenderness, pain, and muscle soreness or stiffness. Other side effects may occur. IMOGAM Rabies-HT immune globulin should not be given in repeated doses once vaccine treatment has begun. IMOGAM Rabies-HT immune globulin is made from components of human blood and, therefore, this vaccine may carry a risk of transmitting infectious material, although careful selection of donors and extensive testing are intended to minimize this risk. Treatment with a rabies immune globulin may not protect all individuals.
For more information about IMOGAM Rabies-HT immune globulin, talk to your health-care professional.
Last modified: 5/2/08
